CY1115138T1 - Παραγωγο 3,8-διαμινοτετραϋδροκινολινης - Google Patents

Παραγωγο 3,8-διαμινοτετραϋδροκινολινης

Info

Publication number
CY1115138T1
CY1115138T1 CY20141100391T CY141100391T CY1115138T1 CY 1115138 T1 CY1115138 T1 CY 1115138T1 CY 20141100391 T CY20141100391 T CY 20141100391T CY 141100391 T CY141100391 T CY 141100391T CY 1115138 T1 CY1115138 T1 CY 1115138T1
Authority
CY
Cyprus
Prior art keywords
group
hydrogen atom
alkyl group
different
diominetetrahrokinolin
Prior art date
Application number
CY20141100391T
Other languages
English (en)
Inventor
Takeshi Watanabe
Masaru Terauchi
Masaaki Nagasawa
Kouichirou Tanaka
Masataka Washiduka
Original Assignee
Zeria Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co., Ltd filed Critical Zeria Pharmaceutical Co., Ltd
Publication of CY1115138T1 publication Critical patent/CY1115138T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)

Abstract

Για παροχή μιας ένωσης η οποία έχει μια δυνητική αγωνιστική δραστικότητα σε GHS-R και η οποία είναι χρήσιμη ως ένας θεραπευτικός παράγοντας για συστημικές εξασθενητικές νόσους όπως η καχεξία. Ένα παράγωγο 3,8-διαμινοτετραϋδροκινολίνης που αναπαρίσταται από τον τύπο (la) (όπου Χ αναπαριστά CH2, C=Ο, CH-OR, CH-SR, ή CH-NRR’˙ m είναι ένας αριθμός από 1 ή 2˙ Ar αναπαριστά μια φαινυλική ομάδα, μια ναφθυλική ομάδα, μια 5-μελή ή 6-μελή αρωματική ετεροκυκλική ομάδα η οποία έχει ένα ή δύο στοιχεία επιλεγμένα από S, Ν και Ο, ή μια παρόμοια ομάδα˙ R1 και R2, τα οποία μπορεί να είναι πανομοιότυπα ή διαφορετικά το ένα από το άλλο, έκαστο αναπαριστά ένα άτομο υδρογόνου ή μια μεθυλική ομάδα˙ R3 αναπαριστά μια C1 έως C6 αλκυλική ομάδα ή μια παρόμοια ομάδα˙ n είναι ένας αριθμός από 0 ή 1˙ R4 και R5, τα οποία μπορεί να είναι πανομοιότυπα ή διαφορετικά το ένα από το άλλο, έκαστο αναπαριστά ένα άτομο υδρογόνου, ή μια C1 έως C6 αλκυλική ομάδα, κλπ.˙ και R6, R7, R και R', τα οποία μπορεί να είναι πανομοιότυπα ή διαφορετικά το ένα από το άλλο, έκαστο αναπαριστά ένα άτομο υδρογόνου ή μια C1 έως C6 αλκυλική ομάδα), ή ένα άλας αυτής.
CY20141100391T 2008-02-08 2014-06-03 Παραγωγο 3,8-διαμινοτετραϋδροκινολινης CY1115138T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008029781 2008-02-08
JP2008277044 2008-10-28
EP09707360.5A EP2241564B1 (en) 2008-02-08 2009-02-06 3,8-diaminotetrahydroquinoline derivative

Publications (1)

Publication Number Publication Date
CY1115138T1 true CY1115138T1 (el) 2016-12-14

Family

ID=40951980

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100391T CY1115138T1 (el) 2008-02-08 2014-06-03 Παραγωγο 3,8-διαμινοτετραϋδροκινολινης

Country Status (20)

Country Link
US (2) US8299255B2 (el)
EP (1) EP2241564B1 (el)
JP (1) JP5493870B2 (el)
KR (1) KR101553725B1 (el)
CN (1) CN101939313B (el)
AU (1) AU2009212645B2 (el)
BR (1) BRPI0907749A2 (el)
CA (1) CA2714480C (el)
CY (1) CY1115138T1 (el)
DK (1) DK2241564T3 (el)
ES (1) ES2464342T3 (el)
HR (1) HRP20140449T1 (el)
MX (1) MX2010008740A (el)
PL (1) PL2241564T3 (el)
PT (1) PT2241564E (el)
RU (1) RU2482117C2 (el)
SI (1) SI2241564T1 (el)
TW (1) TWI422585B (el)
WO (1) WO2009098901A1 (el)
ZA (1) ZA201005346B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328449A (zh) * 2011-01-26 2013-09-25 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
TWI662967B (zh) 2013-03-25 2019-06-21 日商志瑞亞新藥工業股份有限公司 食後期之胃運動亢進劑
CN104193722A (zh) * 2014-08-27 2014-12-10 湖南华腾制药有限公司 一种n-叔丁氧羰基-3-甲胺噻吩的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
JP3817746B2 (ja) 1994-06-20 2006-09-06 株式会社竹屋 パチンコ島台
CA2301566A1 (en) 1997-08-22 1999-03-04 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
RU2277092C2 (ru) * 2000-09-15 2006-05-27 Анормед, Инк. Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5
US7276608B2 (en) * 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators

Also Published As

Publication number Publication date
PT2241564E (pt) 2014-06-12
US20100317693A1 (en) 2010-12-16
EP2241564A1 (en) 2010-10-20
US8299255B2 (en) 2012-10-30
HRP20140449T1 (hr) 2014-06-20
EP2241564B1 (en) 2014-04-30
AU2009212645A1 (en) 2009-08-13
WO2009098901A1 (ja) 2009-08-13
US8501772B2 (en) 2013-08-06
ZA201005346B (en) 2011-11-30
JP5493870B2 (ja) 2014-05-14
AU2009212645B2 (en) 2012-07-19
CN101939313B (zh) 2013-05-22
EP2241564A4 (en) 2011-07-20
MX2010008740A (es) 2010-08-30
CA2714480A1 (en) 2009-08-13
BRPI0907749A2 (pt) 2015-07-21
PL2241564T3 (pl) 2014-09-30
KR101553725B1 (ko) 2015-09-16
TWI422585B (zh) 2014-01-11
ES2464342T3 (es) 2014-06-02
JPWO2009098901A1 (ja) 2011-05-26
US20130012537A1 (en) 2013-01-10
RU2010137336A (ru) 2012-03-20
KR20100116175A (ko) 2010-10-29
CA2714480C (en) 2017-03-28
CN101939313A (zh) 2011-01-05
RU2482117C2 (ru) 2013-05-20
SI2241564T1 (sl) 2014-06-30
TW200940530A (en) 2009-10-01
DK2241564T3 (da) 2014-05-19

Similar Documents

Publication Publication Date Title
CY1123308T1 (el) Αναστολεας ινωσης
CY1118390T1 (el) Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου
CY1124728T1 (el) Παραγωγα βενζοξαβορολης για τη θεραπεια βακτηριακων λοιμωξεων
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
CY1115738T1 (el) Κρυσταλλικα επιδιαλυτωμενα συμπλοκα των παραγωγων (1s)-1,5-anyδpo-1-c-(3-((φainyλ)meθυλ) φαινυλ)-d-γλουσιτολης με αλκοολες οπως αναστολεις sglt2 για τη θεραπευτικη αντιμετωπιση του διαβητη
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
CY1117080T1 (el) Θεραπευτικος παραγοντας για στενωση του σπονδυλικου σωληνα
RS54776B1 (sr) Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera
CY1117481T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης
CY1110232T1 (el) Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
CY1112642T1 (el) Παραγωγα 4-(πυριδιν-4-υλο)-1η-[1,3,5]τριαζιν-2-ονης ως αναστολεις της gsκ3-βετα για τη θεραπεια των νευροεκφυλιστικων ασθενειων
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
EA201290260A1 (ru) Бензимидазол-имидазольные производные
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CY1114112T1 (el) Νεα αρυλαμιδια υποκατεστημενα με πυραζολιο
EA201100447A1 (ru) Органические соединения
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
ECSP10010425A (es) Pirrolopirimidincarboxamidas
CY1111748T1 (el) Παραγωγα 7-αλκυνυλο-1.8-ναφθυριδονων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones